Denali Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:4DN Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
07 Jan 25	Sell€724,446	Ryan Watts	Individual	36,916	€20.08
07 Jan 25	Sell€67,032	Steve Krognes	Individual	3,339	€20.08
07 Jan 25	Sell€297,408	Alexander Schuth	Individual	15,162	€20.08
07 Jan 25	Sell€297,408	Carole Ho	Individual	15,162	€20.08
21 Aug 24	Sell€180,040	Alexander Schuth	Individual	8,353	€22.26
20 Aug 24	Sell€37,006	Steve Krognes	Individual	1,727	€21.43
20 Aug 24	Sell€48,426	Ryan Watts	Individual	2,260	€21.43
20 Aug 24	Sell€52,562	Carole Ho	Individual	2,453	€21.43
13 Aug 24	Sell€48,835	Carole Ho	Individual	2,337	€20.90
13 Aug 24	Sell€47,476	Alexander Schuth	Individual	2,272	€20.90
13 Jun 24	Sell€13,927	Steve Krognes	Individual	688	€20.24
13 Feb 24	Sell€43,809	Alexander Schuth	Individual	2,716	€16.13
13 Feb 24	Sell€44,905	Carole Ho	Individual	2,784	€16.13
13 Feb 24	Sell€154,669	Ryan Watts	Individual	9,589	€16.13
13 Feb 24	Sell€44,357	Steve Krognes	Individual	2,750	€16.13

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 4DN?
Owner Type	Number of Shares	Ownership Percentage
General Public	2,004,651	1.39%
Individual Insiders	6,651,459	4.62%
Public Companies	7,155,243	4.97%
Institutions	128,110,271	89%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.

Top Shareholders

Top 25 shareholders own 82.43% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.58%	BlackRock, Inc.	13,788,517	€284.4m	4.66%	no data
9.27%	Baillie Gifford & Co.	13,345,887	€275.3m	-3.03%	0.11%
7.77%	The Vanguard Group, Inc.	11,177,234	€230.6m	-1.2%	no data
7.45%	Wellington Management Group LLP	10,727,450	€221.3m	9.2%	0.03%
5.5%	Capital Research and Management Company	7,909,114	€163.1m	11%	0.01%
5.44%	FMR LLC	7,828,372	€161.5m	3,260%	0.01%
4.97%	Biogen Inc.	7,155,243	€147.6m	-43.9%	no data
3.72%	Temasek Holdings (Private) Limited	5,355,832	€110.5m	-6.14%	0.09%
3.1%	Crestline Investors Inc.	4,460,732	€92.0m	-6.3%	5.01%
2.95%	State Street Global Advisors, Inc.	4,252,011	€87.7m	-4.12%	no data
2.7%	UBS Asset Management AG	3,890,889	€80.3m	59.9%	0.01%
2.59%	Baker Bros. Advisors LP	3,731,695	€77.0m	0%	0.73%
2.12%	AllianceBernstein L.P.	3,047,264	€62.9m	51%	0.02%
2.05%	Geode Capital Management, LLC	2,955,477	€61.0m	-0.91%	no data
1.99%	T. Rowe Price Group, Inc.	2,869,795	€59.2m	27.2%	no data
1.56%	Ryan Watts	2,241,211	€46.2m	0%	no data
1.47%	Marc Tessier-Lavigne	2,111,441	€43.6m	0%	no data
1.39%	Camber Capital Management LP	2,000,000	€41.3m	0%	1.73%
1.37%	Marshall Wace LLP	1,967,141	€40.6m	-18.7%	0.06%
1.08%	Dimensional Fund Advisors LP	1,559,442	€32.2m	10%	no data
1.06%	Morgan Stanley, Investment Banking and Brokerage Investments	1,531,032	€31.6m	48.5%	no data
0.91%	BNY Asset Management	1,315,502	€27.1m	-13.8%	no data
0.86%	Principal Global Investors, LLC	1,238,499	€25.5m	13.8%	0.01%
0.76%	Artisan Partners Limited Partnership	1,091,018	€22.5m	-4.42%	0.02%
0.75%	Northern Trust Global Investments	1,085,642	€22.4m	0.25%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/09 07:26
End of Day Share Price	2025/01/09 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Denali Therapeutics Inc. is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joel Beatty	Baird
Caroline Palomeque	Berenberg
Tazeen Ahmad	BofA Global Research